S1801

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Contact phone
Clinical Trials Office – 517.364.9400
Principal investigator
Gordan Srkalovic
Trial Category
Cancer
Trial SubCategory
Melanoma